Bovine liver dihydrofolate reductase: purification and properties of the enzyme
- PMID: 45
- DOI: 10.1021/bi00695a005
Bovine liver dihydrofolate reductase: purification and properties of the enzyme
Abstract
A purification procedure is reported for obtaining bovine liver dihydrofolate reductase in high yield and amounts of 100-200 mg. A key step in the procedure is the use of an affinity gel prepared by coupling pteroyl-L-lysine to Sepharose. The purified reductase has a specific activity of about 100 units/mg and is homogeneous as judged by analytical ultracentrifugation, polyacrylamide gel electrophoresis, and titration with methotrexate. The products of the first step of Edman degradation indicated a minimum purity of 79%. The reductase has a molecular weight of about 21500 on the basis of amino acid composition and 22100 +/- 300 from equilibrium sedimentation. It is not inhibited by antiserum to the Streptococcus faecium reductase (isoenzyme 2). Unlike the reductase of many other vertebrate tissues, the bovine enzyme is inhibited by mercurials rather than activated and it has a single pH optimum at both low and high ionic strength. However, the position of the pH optimum is shifted and the activity increased by increasing ionic strength. Automatic Edman degradation has been used to determine 34 of the amino-terminal 37 amino acid residues. Considerable homology exists between this region and the corresponding regions of the reductase from S. faecium and from Escherichia coli. This strengthens the idea that this region contributes to the structure of the binding site for dihydrofolate.
Similar articles
-
Purification and properties of Escherichia coli dihydrofolate reductase.Biochemistry. 1975 Dec 2;14(24):5267-73. doi: 10.1021/bi00695a006. Biochemistry. 1975. PMID: 46
-
Dihydrofolate reductase from bovine liver. Enzymatic and structural properties.Eur J Biochem. 1975 Dec 1;60(1):9-15. doi: 10.1111/j.1432-1033.1975.tb20969.x. Eur J Biochem. 1975. PMID: 1204646
-
Age-dependent expression of a novel protein in mouse liver immunologically and functionally homologous with dihydrofolate reductase.Biochim Biophys Acta. 1989 Oct 13;993(1):56-62. doi: 10.1016/0304-4165(89)90143-8. Biochim Biophys Acta. 1989. PMID: 2804123
-
Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells.Biochemistry. 1983 Feb 1;22(3):633-9. doi: 10.1021/bi00272a017. Biochemistry. 1983. PMID: 6838817
-
Purification and properties of dihydrofolate reductase from an amethopterin-resistant strain of Streptococcus faecium.Biochemistry. 1972 Apr 11;11(8):1528-34. doi: 10.1021/bi00758a030. Biochemistry. 1972. PMID: 5021603 No abstract available.
Cited by
-
Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites.Cancer Chemother Pharmacol. 1988;22(2):175-7. doi: 10.1007/BF00257318. Cancer Chemother Pharmacol. 1988. PMID: 3409449
-
Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model.Cancer Immunol Immunother. 1991;32(5):331-4. doi: 10.1007/BF01789052. Cancer Immunol Immunother. 1991. PMID: 1998974 Free PMC article.
-
Maintenance of dihydrofolate reductase enzyme after disappearance of DHFR mRNA during muscle cell differentiation.In Vitro Cell Dev Biol. 1989 Aug;25(8):697-704. doi: 10.1007/BF02623722. In Vitro Cell Dev Biol. 1989. PMID: 2768131
-
Conjugation of methotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo.Cancer Immunol Immunother. 1985;19(3):211-4. doi: 10.1007/BF00199228. Cancer Immunol Immunother. 1985. PMID: 3847291 Free PMC article.
-
Synthesis of site-specific methotrexate-IgG conjugates. Comparison of stability and antitumor activity with active-ester-based conjugates.Cancer Immunol Immunother. 1989;29(4):293-302. doi: 10.1007/BF00199218. Cancer Immunol Immunother. 1989. PMID: 2787696 Free PMC article.